Clinical Trial Update: An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma [Phase 1]

View source ↗

Summary

A Phase 1 exploratory pharmacogenomic study evaluating cetuximab (Erbitux) as monotherapy in patients with metastatic non-small cell lung cancer; the trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | Phase 1 | Status: COMPLETED